Lilly and Boehringer Ingelheim have gained EU approval for their biosimilar version of Sanofi's blockbuster insulin product Lantus (insulin glargine). The Europe-wide approval is the first ever ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback